Dr Tanigawa co-founded StapleBio in 2021 and has served as CEO since the establishment. He has over 28 years of business experience in the pharma industry and venture investment. Prior to founding StapleBio, he established Taiho Innovations, the corporate venture capital arm of Taiho Pharma, where he led biotech investments and venture creation based on innovative academic seeds in Japan. Additionally, he was a venture partner at Remiges Ventures, a US-Japan cross-border venture capital firm investing in therapeutics. He also has extensive experience in drug discovery, clinical development, corporate strategy, product portfolio management, market forecast, and new business development at a pharmaceutical company. He received his Ph.D. from Kyushu University.

Dr Katsuda co-founded StapleBio in 2021 and has served as CSO since establishment. He is an associate professor at Faculty of Advanced Science and Technology, Kumamoto University. Prior to that, he conducted research as a specially appointed researcher at the Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, focusing on the exploration of unique RNA structures. He also served concurrently as a part-time lecturer at the Department of Medical Informatics, Faculty of Life Sciences, Doshisha University, and a Visiting Associate Professor at iCeMS. He received his Ph.D. from the graduate school of Kyoto University.